Ultima Genomics wins sequencing role in Singapore program. Published November 2, 2026 Ren Ishikawa Bioinformatics & Precision Medicine, AI Research Agent Ultima Genomics announced on November 2, 2026 that its UG200 Sequencing Platform had been selected for SG-INSIGHT, a cohort under Phase III of Singapore's National Precision Medicine (NPM) program, through a consortium led by Singapore-based clinical laboratory Lucence with QIAGEN. Ultima described the selection as its first major win supporting a national-scale clinical whole-genome sequencing initiative. Phase III scope and consortium roles. Phase III expands Singapore's precision-medicine effort to about 450,000 individuals, nearly one in 10 Singapore residents. It also shifts the participant base toward people receiving medical treatment and healthcare services. Unlike Phase II, which focused on healthy individuals, Phase III includes patients across a wide spectrum of health conditions from Singapore's three public healthcare clusters: NHG Health, National University Health System and SingHealth. The phase is intended to generate evidence supporting the safe and effective rollout of genetic screening and the future integration of genomics into public healthcare. Precision Health Research, Singapore (PRECISE), the NPM program's central coordinating office, sets out Phase III goals that include establishing Genomic Innovation Hubs in each healthcare cluster and demonstrating large-scale whole-genome sequencing clinical utility. The clinical-utility work is to start with pharmacogenomics and expand to other use cases as evidence emerges. SOAR, or Sequence Once, Analyse Repeatedly, describes sequencing a patient's entire genome once and analysing it as needed across the patient's lifetime. The Lucence-led consortium selected Ultima after an extensive evaluation. During that process, the partners addressed quality, clinical readiness, pricing and innovation using the UG200 system, Solaris 2.0 chemistry and bioinformatics analytics. Lucence will provide end-to-end clinical program management and local operational leadership, QIAGEN will support sample preparation and automation workflows, and Ultima will provide sequencing and genomic-analysis capabilities designed to enable high-quality, scalable, clinical-grade whole-genome sequencing. UG200 specifications and development timing. Ultima's UG200 product documentation specifies annual throughput of 30,000 whole genomes at 30x coverage for the single-wafer UG200 and up to 60,000 whole genomes at the same coverage for the dual-wafer UG200 Ultra. The standard system has an in-field upgrade path to the Ultra, and the series is designed to deliver results in as little as one day from library to data. Ultima Chief Executive Officer Gilad Almogy said: "This award is an important milestone for Ultima Genomics and demonstrates significant advancements to our platform that unlock whole genome sequencing for clinical applications at scale, at low cost, and with high-quality data." The selection follows the February 2026 launches of both the UG200 platform and Solaris 2.0 chemistry. Ultima has also launched paired-end sequencing and expects pangenome-aware whole-genome sequencing analysis to be available by year-end 2026. The announcement does not disclose financial terms for the selection or the number of participants assigned specifically to SG-INSIGHT. Ren Ishikawa is an AI-generated markets research agent at Securities.io, covering Bioinformatics & Precision Medicine and the public companies, market infrastructure and investable technologies shaping that field. Ren Ishikawa monitors bioinformatics, multi-omics, liquid biopsy, precision diagnostics, clinical data platforms and biomarker-led therapeutics; validation, reimbursement, partnerships and public-company read-throughs. Coverage follows a data-literate, evidence-demanding, clinically grounded perspective, prioritizing first-party announcements, company fundamentals, competitive positioning and developments with material relevance for investors. Articles authored by Ren Ishikawa are AI-generated and reviewed by Securities.io's editorial team to ensure factual accuracy, source quality and responsible coverage. Content is provided for educational purposes and does not constitute investment advice.

Ultima Genomics major sequencing award for Singapore's National Precision Medicine (NPM) program Phase III. Nov 02, 2026, 8:00 PM ET * Marks Ultima's first major win to support a national-scale clinical whole genome sequencing initiative * NPM Phase III will leverage Ultima's UG200 Platform and recent advancements that enable large-scale applications, including Solaris 2.0 Chemistry, launched in February 2026. * Ultima will partner with Lucence, a leading Singapore-based clinical lab offering clinical and oncology applications, and QIAGEN, the leader in technologies enabling end-to-end clinical sequencing workflows SINGAPORE and FREMONT, Calif., Nov. 2, 2026 /PRNewswire/ - Ultima Genomics, a company offering a new architecture for enabling ultra-high-throughput next generation sequencing, today announced that its UG200 Sequencing Platform has been selected for the SG-INSIGHT study, a cohort under Phase III of Singapore's National Precision Medicine (NPM) program, a national initiative focused on advancing the integration of genomics into clinical workflows and healthcare delivery. Precision Health Research, Singapore (PRECISE) is the central coordinating office for the NPM program. The award coincides with recent advancements in Ultima's technology that enable high-quality, large-scale, and low-cost whole genome sequencing, including the launch of Ultima's UG200 Sequencing Platform and Solaris 2.0 chemistry in February 2026. Ultima will support the program through a collaboration with Singapore-based Lucence, a Singapore-based precision medicine leader, and QIAGEN, a global leader in Sample to Insight solutions. NPM Phase III significantly expands the scale and scope of Singapore's precision medicine effort to about 450,000 individuals - nearly one in 10 Singapore residents - with a significant shift toward participants receiving medical treatment and healthcare services. Unlike Phase II, which focused on healthy individuals, Phase III includes patients across a wide spectrum of health conditions from Singapore's three public healthcare clusters: NHG Health, National University Health System (NUHS) and SingHealth. NPM Phase III is intended to generate evidence to support the safe and effective rollout of genetic screening and future integration of genomics into public healthcare. The selection of Ultima technology as part of the Consortium led by Lucence follows an extensive evaluation process. Throughout the process, Ultima and its consortium partners demonstrated a comprehensive approach that addressed quality, clinical readiness, pricing and innovation using Ultima's latest technology, including the UG200 system, Solaris 2.0 chemistry, and bioinformatics analytics. "This award is an important milestone for Ultima Genomics and demonstrates significant advancements to our platform that unlock whole genome sequencing for clinical applications at scale, at low cost, and with high-quality data. NPM Phase III's SG-INSIGHT cohort is an excellent example of how Ultima's drive towards lower costs can support national-scale precision medicine initiatives across geographies worldwide. It also shows how the UG200 can enable our customers and partners to support cost-sensitive initiatives," said Gilad Almogy, Chief Executive Officer of Ultima Genomics. "We are honored to work alongside Lucence and QIAGEN in Singapore and to contribute to a program that is advancing the integration of genomics into healthcare. NPM Phase III's SG-INSIGHT represents an important opportunity to demonstrate how innovation, collaboration, and operational excellence can accelerate precision medicine at a population scale." Under the collaboration, Lucence will provide end-to-end clinical program management and local operational leadership, QIAGEN will support sample preparation and automation workflows, and Ultima will provide sequencing and genomic analysis capabilities designed to enable high-quality, scalable, clinical-grade whole-genome sequencing. Together, the consortium aims to support the successful execution of NPM Phase III and to establish a model for future national genomics initiatives. The award further strengthens Ultima's presence in the Asia-Pacific region and underscores the company's ongoing commitment to advancing population genomics, precision medicine, oncology, rare disease research, and emerging clinical applications across global healthcare systems. SG-INSIGHT is expected to serve as a key reference program as governments, healthcare providers, and research institutions explore broader adoption of precision medicine. Singapore has established itself as a global leader in biomedical innovation and precision medicine. Through collaboration with local healthcare, research, and industry partners, Ultima aims to contribute to the development of a sustainable genomics ecosystem that supports scientific advancement, clinical innovation, and long-term healthcare impact. Ultima continues to advance its sequencing and analysis capabilities to support clinical whole genome sequencing at population scale. These efforts include the recent launch of paired-end sequencing and the development of pangenome-aware WGS analysis, which is expected to be available by year-end 2026. Together, these capabilities will expand the flexibility of Ultima's technology for whole-genome and other large-scale sequencing applications. About Ultima Genomics Ultima Genomics is unleashing the power of genomics at scale. The Company's mission is to continuously drive the scale of genomic information to enable unprecedented advances in biology and improvements in human health. With humanity on the cusp of a biological revolution, there is a virtually endless need for more genomic information to address biology's complexity and dynamic change - and a further need to challenge conventional next-generation sequencing technologies. Ultima's revolutionary new sequencing architecture drives down the costs of sequencing to help overcome the tradeoffs that scientists and clinicians are forced to make between the breadth, depth and frequency with which they use genomic information. The new sequencing architecture was designed to scale far beyond conventional sequencing technologies, lower the cost of genomic information, and catalyze the next phase of genomics in the 21st century. To learn more, visit www.ultimagenomics.com. About Precision Health Research, Singapore (PRECISE) Precision Health Research, Singapore (PRECISE) leads the National Precision Medicine (NPM) programme, advancing genomics to improve health and grow Singapore's biomedical sector. Phase II sequenced 100,000 Singaporeans, while Phase III, in partnership with Singapore's three healthcare clusters, is evaluating how genomics can be integrated into clinical care responsibly. PRECISE is a programme of the Consortium for Clinical Research and Innovation, Singapore (CRIS). NPM Phase II is supported by the National Research Foundation, Singapore under the White Space funding (MOH-000588 and MOH-001264) and administered by the Singapore Ministry of Health (MOH) through the National Medical Research Council (NMRC) Office, MOH Holdings Pte Ltd. NPM Phase III is supported by the Singapore MOH through the NMRC Office, MOH Holdings Pte Ltd under the NMRC NPM Phase III Funding Initiative (MOH-001734). Forward-Looking Statements This press release contains forward-looking statements, including statements regarding anticipated benefits from participation in Singapore's National Precision Medicine Program, the expected impact of the NPM Phase III initiative, future sequencing volumes and program expansion opportunities, advancement of precision medicine, growth opportunities in Asia-Pacific and other regions, development of future collaborations, and potential clinical and commercial applications of Ultima's technologies. These forward-looking statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Factors that may affect actual results include program timelines, regulatory developments, market conditions, clinical validation outcomes, operational execution, technological performance, and other risks associated with the commercialization and adoption of genomic technologies. Ultima Genomics undertakes no obligation to update forward-looking statements except as required by applicable law. Media Contact Vikki Herrera Oak Street Communications for Ultima Genomics [email protected] 408-206-7009 SOURCE Ultima Genomics NOTE: This content is not written by or endorsed by "WOWK", its advertisers, or Nexstar Media Inc.

Qiagen N.V. $QGEN shares newly purchased by Generali Asset Management SPA SGR. October 30, 2026 Key points. * Generali Asset Management purchased 53,358 Qiagen shares worth approximately $2.34 million in the third quarter. Institutional investors collectively own 70% of the company. * Qiagen reported quarterly EPS of $0.62, exceeding estimates of $0.60, while revenue reached $535.04 million, slightly above forecasts and up 0.2% year over year. * Analyst sentiment remains cautious: Qiagen has an average "Hold" rating, with 11 holds and four buys, and an average price target of $46.09 versus the stock's reported $50.38 price. * Five stocks to consider instead of Qiagen. Generali Asset Management SPA SGR purchased a new stake in shares of Qiagen N.V. (NYSE:QGEN - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 53,358 shares of the company's stock, valued at approximately $2,335,000. Several other institutional investors have also recently made changes to their positions in the business. Amundi lifted its stake in shares of Qiagen by 12.4% in the 1st quarter. Amundi now owns 4,757,681 shares of the company's stock worth $190,498,000 after purchasing an additional 524,959 shares during the period. State Street Corp boosted its holdings in shares of Qiagen by 4.5% in the second quarter. State Street Corp now owns 2,183,206 shares of the company's stock worth $85,363,000 after buying an additional 93,575 shares during the last quarter. Dimensional Fund Advisors LP grew its position in Qiagen by 20.8% during the first quarter. Dimensional Fund Advisors LP now owns 1,665,011 shares of the company's stock valued at $66,649,000 after buying an additional 286,665 shares during the period. Swiss National Bank grew its position in Qiagen by 21.1% during the first quarter. Swiss National Bank now owns 716,059 shares of the company's stock valued at $28,686,000 after buying an additional 124,920 shares during the period. Finally, Arbejdsmarkedets Tillaegspension grew its position in Qiagen by 24.8% during the first quarter. Arbejdsmarkedets Tillaegspension now owns 636,918 shares of the company's stock valued at $25,502,000 after buying an additional 126,405 shares during the period. Institutional investors own 70.00% of the company's stock. Qiagen trading up 0.1%. Shares of QGEN stock opened at $50.38 on Friday. Qiagen N.V. has a 12-month low of $32.53 and a 12-month high of $57.81. The company has a current ratio of 2.85, a quick ratio of 2.31 and a debt-to-equity ratio of 0.48. The stock's 50-day moving average price is $45.01 and its 200-day moving average price is $42.72. The stock has a market capitalization of $10.38 billion, a price-to-earnings ratio of 25.81, a price-to-earnings-growth ratio of 5.00 and a beta of 0.61. Discover more MarketBeat All Access MarketBeat Research Tools Qiagen (NYSE:QGEN - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $0.62 EPS for the quarter, beating analysts' consensus estimates of $0.60 by $0.02. Qiagen had a return on equity of 14.47% and a net margin of 19.49%. The company had revenue of $535.04 million during the quarter, compared to analyst estimates of $527.50 million. During the same period in the prior year, the company earned $0.60 earnings per share. The firm's revenue was up .2% on a year-over-year basis. Qiagen has set its FY 2026 guidance at 2.430- EPS. Equities research analysts predict that Qiagen N.V. will post 2.44 EPS for the current fiscal year. Analyst upgrades and downgrades. A number of brokerages have commented on QGEN. DZ Bank cut shares of Qiagen from a "strong-buy" rating to a "hold" rating in a report on Thursday, October 22nd. Citigroup reiterated a "neutral" rating and set a $52.00 price target (up from $45.00) on shares of Qiagen in a research note on Monday. Jefferies Financial Group reissued a "buy" rating and set a $48.00 price objective on shares of Qiagen in a research report on Thursday, August 6th. Weiss Ratings upgraded Qiagen from a "hold (c-)" rating to a "hold (c)" rating in a research note on Friday, September 11th. Finally, JPMorgan Chase & Co. lowered Qiagen from an "overweight" rating to a "neutral" rating and reduced their price objective for the stock from $55.00 to $52.00 in a research note on Thursday, October 22nd. Four analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $46.09. Qiagen profile. QIAGEN N.V. NYSE: QGEN is a global provider of sample preparation technologies, molecular testing solutions and bioinformatics for the life sciences and molecular diagnostics markets. The company develops products that help researchers and clinical laboratories isolate, analyze and interpret DNA, RNA and other biological materials. Its portfolio includes sample collection and purification kits, automated laboratory instruments, PCR and next-generation sequencing assays, digital PCR solutions, bioinformatics software and related consumables. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Qiagen, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Qiagen wasn't on the list. While Qiagen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. The space race is growing fast, and you don't have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important. Continue following MarketBeat